Literature DB >> 11707003

HLA-B27 polymorphism.

E J Ball1, M A Khan.   

Abstract

HLA-B27 is a serologic specificity that encompasses 25 different alleles that encode 23 different products (proteins): HLA-B*2701 to B*2723. These alleles are also called subtypes of HLA-B27, and they may have evolved from the most widespread subtype, B*2705. These subtypes are distinguished from changes mostly in exons 2 and 3, which encode the alpha 1 and alpha 2 domains of the B27 molecule, respectively. Occurrence of ankylosing spondylitis (AS) or related spondyloarthropathy (SpA) has thus far been documented in subjects possessing any one of the first ten (B*2701 to B*2710) subtypes studied. However, B*2706 in Southeast Asian and B*2709 in the Italian island population of Sardinia seem not to be associated with AS. The 13 most recent subtypes have not yet been studied for disease association. It is important to investigate which of them are and are not associated with AS and related SpA, and whether certain subtypes show any preferential association with some of the clinical features or forms of these diseases among the various ethnic/racial populations and geographic regions of the world. This is expected to provide clues as to the mechanism of disease association, and one of the strongest reasons to study the B27 subtypes is to learn the effects of the sequence variations on the peptide-binding specificity of the molecule. Among these peptides may be the putative arthritogenic peptide(s).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11707003     DOI: 10.1016/s1297-319x(01)00294-9

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  8 in total

1.  HLA-B27 subtypes in Turkish patients with ankylosing spondylitis and healthy controls.

Authors:  Muradiye Acar; Tulin Cora; Recep Tunc; Hasan Acar
Journal:  Rheumatol Int       Date:  2011-09-17       Impact factor: 2.631

Review 2.  Ankylosing spondylitis: an overview.

Authors:  J Sieper; J Braun; M Rudwaleit; A Boonen; A Zink
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

3.  A proposed HLA-B*27 screening method for ankylosing spondylitis detection based on tag-single nucleotide polymorphisms: a preliminary study.

Authors:  Gabriela Angélica Martínez-Nava; Yessica Zamudio-Cuevas; Ninoska Aleida Terrazas-Ontiveros; Karina Martínez-Flores; Rolando Espinosa-Morales; Fernando Mijares-Díaz; Shaila Monserrat Juárez-Barreto; Carlos Lozada-Pérez; Margarita Valdés-Flores; Roberto Sánchez-Sánchez; Alberto Hidalgo-Bravo; Javier Fernández-Torres
Journal:  Mol Biol Rep       Date:  2021-10-13       Impact factor: 2.316

4.  HLA B27 allele types in homogeneous groups of juvenile idiopathic arthritis patients in Latvia.

Authors:  Valda Stanevicha; Jelena Eglite; Dace Zavadska; Arturs Sochnevs; Arina Lazareva; Dinara Guseinova; Ruta Shantere; Dace Gardovska
Journal:  Pediatr Rheumatol Online J       Date:  2010-10-14       Impact factor: 3.054

5.  Ankylosing spondylitis in rheumatology patients in Ouagadougou (Burkina Faso).

Authors:  Dieu-Donné Ouédraogo; Hervé Tiéno; Hyacinthe Kaboré; Elisabeth Palazzo; Oliver Meyer; Joseph Youssouf Drabo
Journal:  Clin Rheumatol       Date:  2009-09-02       Impact factor: 2.980

6.  Low frequency of HLA-B27 in ankylosing spondylitis and its relationship with clinical findings in patients from Turkey.

Authors:  Sevde Nur Fırat; Ayten Yazıcı; Barış Yılmazer; Fulya Coşan; Hakan Savlı; Ayşe Cefle
Journal:  Eur J Rheumatol       Date:  2017-10-25

7.  Comparison of HLA-B*27 subtypes between Chinese patients with ankylosing spondylitis and non-ankylosing spondylitis carriers.

Authors:  Fangjun Luo; Zhigang Zhao; Jie Zhang; Jianhang Leng
Journal:  J Int Med Res       Date:  2019-06-10       Impact factor: 1.671

8.  Ankylosing spondylitis: from cells to genes.

Authors:  José Francisco Zambrano-Zaragoza; Juan Manuel Agraz-Cibrian; Christian González-Reyes; Ma de Jesús Durán-Avelar; Norberto Vibanco-Pérez
Journal:  Int J Inflam       Date:  2013-07-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.